Roche- Zealand obesity drug delivers 9.2% weight loss in mid-stage trial
Zealand Pharma’s mid-stage results show its obesity/diabetes candidate produced up to 9.2% body weight loss in trials run with Roche. The data underscore potential for the collaboration to progress to later-stage studies and possibly milestone payments, which could improve Zealand’s collaboration economics and signal upside for Roche’s obesity/diabetes portfolio.
View signal analysis